A phase 2 trial of BioDiem's seasonal live attenuated influenza vaccine (LAIV) in European adults.

Trial Profile

A phase 2 trial of BioDiem's seasonal live attenuated influenza vaccine (LAIV) in European adults.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2010

At a glance

  • Drugs Influenza vaccine live attenuated (Nasovac-S) (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors BioDiem; Nobilon International
  • Most Recent Events

    • 26 Feb 2010 Results from this trial are expected later in 2010, according to a BioDiem media release.
    • 13 Oct 2009 Status changed from planning to recruiting according to a Schering-Plough media release.
    • 13 Oct 2009 A schering-Plough media release reported that the first patient was successfully dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top